Costs of parkinson's disease in a privately insured population

PharmacoEconomics

Volumn 31, Issue 9, 2013, Pages 799-806

  Johnson, Scott J ^a   Kaltenboeck, Anna ^a   Diener, Melissa ^a   Birnbaum, Howard G ^a   Grubb, Elizabeth ^b   Castelli Haley, Jane ^b   Siderowf, Andrew D ^c  

^a ANALYSIS GROUP   (United States)

^b Teva Neuroscience   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA; LEVODOPA;

ADULT; ARTICLE; DEVICES; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; OUTPATIENT CARE; PARKINSON DISEASE; PRIORITY JOURNAL;

ABSENTEEISM; AMBULATORY CARE; CASE-CONTROL STUDIES; COST OF ILLNESS; COSTS AND COST ANALYSIS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; PARKINSON DISEASE; UNITED STATES;

EID: 84883531827     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0075-0     Document Type: Article

References (31)

1. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-6. (Pubitemid 46184217)
2. Huse DM, Castelli-Haley J, Orsini LS, et al. Patterns of initial pharmacotherapy for Parkinson's disease in the United States. J Geriatr Psychiatry Neurol. 2006;19:91-7. (Pubitemid 43726028)
3. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/Ethnicity. Am J Epidemiol. 2003;157(11):1015-22. (Pubitemid 36628805)
4. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-42.
5. Poewe W. The natural history of Parkinson's disease. J Neurol. 2006; 253Suppl7:VII2-6.
6. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000;69:308-12. (Pubitemid 30636233)
7. Keranen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord. 2003;9:163-8. (Pubitemid 36173566)
8. Schenkman M, Zhu CW, Cutson TM, et al. Longitudinal evaluation of economic and physical impact of Parkinson's disease. Parkinsonism Relat Disord. 2001;8:41-50. (Pubitemid 32694658)
9. Whetten-Goldstein K, Sloan F, Kulas E, et al. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc. 1997;45:844-9. (Pubitemid 27289932)
10. Kaltenboeck A, Johnson SJ, Davis MR, et al. Direct costs and survival of Medicare beneficiaries with early and advanced Parkinson's disease. Parkinsonism Relat Disord. 2012;18(4):321-6.
11. Rubenstein LM, DeLeo A, Chrischilles EA. Economic and health-related quality of life considerations of new therapies on Parkinson's disease. Pharmacoeconomics. 2001;19:729-52. (Pubitemid 32664731)
12. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilization in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics. 2001;19:1012-38.
13. Leibson CL, Long KH, Maraganore DM, et al. Direct medical costs associated with Parkinson's disease: a population-based study. Mov Disord. 2006;21:1864-71. (Pubitemid 44848932)
14. Pressley JC, Louis ED, Tang MX, et al. The impact of comorbid disease and injuries on resource use and expenditures in Parkinsonism. Neurology. 2003;60(1):87-93. (Pubitemid 36070650)
15. McCrone P, Allcock LM, Burn DJ. Predicting the cost of Parkinson's disease. Mov Disord. 2007;22(6):804-12. (Pubitemid 46800101)
16. Dodel RC, Singer M, Köhne-Volland R, et al. The economic impact of Parkinson's disease: an estimation based on a 3-month prospective analysis. Pharmacoeconomics. 1998;14(3):299-312. (Pubitemid 28416933)
17. LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics. 1999;16:59-69. (Pubitemid 29330472)
18. Master Drug Data Base (MDDB(r)) v2.5 Documentation Manual. Indianapolis, IN: Wolters Kluwer Health, Inc.; 2005
19. Master Drug Data Base v2.5 (MDDB(r)). U.S. Food and Drug Administration (2010). http://www.medi-span.com/master-drug-database.aspx. Accessed 7 September 2010
20. National Drug Code Query (2010). http://www.accessdata.fda.gov/scripts/ cder/ndc/activeingredient.cfm. Accessed 15 July 2010
21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-9.
22. National Center for Health Statistics. Health, United States, 2011: With Special Feature on Socioeconomic Status and Health. Hyattsville, MD. 2012. http://www.cdc.gov/nchs/data/hus/hus11.pdf#139. Accessed April 19 2013.
23. Noyes K, Liu H, Yue L, et al. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries. Mov Disord. 2006;21:362-72.
24. Huse DM, Schulman K, Orsini L, et al. Burden of illness in Parkinson's disease. Mov Disord. 2005;20(11):1449-54. (Pubitemid 43072653)
25. Bundorf MK, Royalty A, Baker LC. Health care cost growth among the privately insured. Health Aff (Millwood). 2009;28:1294-304. (Costs inflation adjusted to 2010 dollars using the Consumer Price Index for medical care).
26. Laliberté F, Bookhart BK, Vekeman F, et al. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a Managed Care Perspective. J Manag Care Pharm. 2009;15:312-22. (Costs inflation adjusted to 2010 dollars using the Consumer Price Index for medical care).
27. Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22:3524-30. (Costs inflation adjusted to 2010 dollars using the Consumer Price Index for medical care). (Pubitemid 41109929)
28. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5(3):235-45. (Pubitemid 43238347)
29. Müller T, Woitalla D. Quality of life, caregiver burden and insurance in German patients with Parkinson's disease. Eur J Neurol. 2010;17(11):1365-9.
30. Müller T, Voß B, Hellwig K, Przuntek H. Treatment benefit and daily drug costs in Parkinson's disease clinics. CNS Drugs. 2004;18(2):105-11. (Pubitemid 38293595)
31. Johnson S, Davis M, Kaltenboeck A, et al. Early retirement and income loss in patients with early and advanced Parkinson's disease. Appl Health Econ Health Pol. 2011;9(6):367-76.